Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus Authors: Caterina Tramontozzi, Anna Riccio, Simone La Frazia, Valentina Svicher, M. Gabriella Santoro Published: 2026 ABSTRACT Highlights•RSV is the leading cause of hospitalization in infants with respiratory infections.•Older adults may also develop severe RSV disease and need hospitalization.•While prevention measures are available, there is no effective drug treatment for RSV.•Indomethacin has potent antiviral activity against RSV in human respiratory cells.•Indomethacin acts at post-entry level, interfering with RSV Fusion protein expression. Introduction Respiratory syncytial virus (RSV) is a filamentous enveloped RNA virus classified within the Pneumoviridae family. The virion contains a negative-sense, single-stranded RNA genome comprising 10 genes encoding 11 structural and non-structural proteins, surrounded by a lipid bilayer displaying the fusion (F), attachment (G) and, to a lower extent, small hydrophobic (SH) proteins, which play distinct roles in infection (Langedijk & Bont, 2023). The F-protein, which mediates fusion between the viral envelope and airway epithelial cells, is critical for infection; notably, F-protein is also responsible for fusion of infected cells with adjacent cells, leading to multinucleate syncytium formation (Langedijk & Bont, 2023). RSV is a ubiquitous pathogen generally transmitted through close contact and aerosolized droplets; there are two major RSV subtypes, A and B, both of which are known to circulate at varying levels depending on the RSV season (Nuttens et al., 2024). Whereas in most people it causes mild respiratory illness, RSV represents the leading cause of hospitalization in young children under 5-years of age with acute respiratory tract infections, particularly in infants younger than six months who are at greater risk for bronchiolitis and severe pneumonia; in 2019 alone, RSV was estimated to be responsible for over 100,000 deaths globally among children under five-years of age (Li et al., 2022). In addition to young children, older adults, especially those with comorbidities, are also susceptible to severe outcomes from RSV infection (Langedijk & Bont, 2023; Nuttens et al., 2024), underscoring the need for effective anti-RSV interventions. Until recently no effective vaccine was available and RSV prophylaxis has relied on palivizumab, a short-term monoclonal antibody administered monthly to high-risk infants (Langedijk & Bont, 2023). Two recombinant prefusion F-protein-based (RSVpreF) vaccines, Arexvy and Abrysvo, are now available for use in adults aged 60 years and older; Abrysvo has been recently authorized also for administration to pregnant women to protect newborns during their first six months of life (Du et al., 2025). In addition, an mRNA-based RSVPreF vaccine recently received FDA-approval (Du et al., 2025). Alongside these vaccines, a long-acting monoclonal antibody, nirsevimab, has been recently introduced for passive immunization of both preterm and term infants against RSV-disease in several countries (Drysdale et al., 2023). Recently, a second long-acting antibody, clesrovimab, also received US approval for preventing RSV lower respiratory tract disease in neonates and infants (Syed, 2025). Monoclonal antibodies prophylaxis, however, remains expensive and is not suitable for widespread application. While some F-protein inhibitors are being investigated in randomized controlled trials [RV521 (sisunatovir) and AK0529 (ziresovir)], RSV disease treatment is restricted to symptomatic therapy; the antiviral ribavirin, that was reported to be effective against RSV in-vitro, was found to have limited efficacy in-vivo and is no longer recommended (Langedijk & Bont, 2023). Therefore, identifying novel antiviral agents remains a high priority. Indomethacin (INDO), a non-steroidal anti-inflammatory drug commonly prescribed for its potent analgesic and anti-inflammatory actions, acts as a non-selective inhibitor of cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2), the key enzymes for prostaglandins and thromboxane synthesis (Rouzer & Marnett, 2009). COX-1 is constitutively expressed, while COX-2 is primarily an inducible isoform, whose expression is activated in response to a variety of stimuli, such as cytokines, endotoxin, hyperthermia and viral infection, including RSV infection (Richardson et al., 2005; Rossi et al., 2012; Rouzer & Marnett, 2009; Shirey et al., 2014). Beyond its anti-inflammatory effects, indomethacin was found to possess antiviral properties against several DNA and RNA viruses in both in-vitro and in-vivo models, including herpesvirus (Zhu et al., 2002) and rotavirus (Rossen et al., 2004). Previous studies from our group have shown that INDO is also effective against both negative-sense RNA viruses (Amici et al., 2015) and positive-sense RNA viruses, such as canine and human coronaviruses, including SARS-CoV-1 (Amici et al., 2006; Tramontozzi et al., 2024). More recently, indomethacin has also shown promising outcomes in clinical trials involving SARS-CoV-2-infected patients (Ravichandran et al., 2022). In this study, we present evidence that INDO effectively inhibits RSV replication in different types of human respiratory cells, acting at the post-entry stage. Materials and methods Cell culture and treatments Human epithelial HEp-2 cells, alveolar type II-like epithelial A549 cells, normal lung MRC-5 fibroblasts and bronchial epithelial 16HBE cells (ATCC; Manassas, VA) were grown in either RPMI-1640 (Euroclone; HEp-2 and A549), DMEM (Euroclone; 16HBE) or EMEM (ATCC; MRC-5) medium, supplemented with 2 mM glutamine, 10% fetal calf serum (FCS) and antibiotics. Indomethacin (INDO, Sigma) and aspirin (ASA, Sigma), dissolved in ethanol stock solution, and Ribavirin (RBV, Sigma), dissolved in water, were diluted in culture medium prior to addition to infected cells; controls received equal amounts of vehicle. Cell viability was determined by MTT assay in mock-infected INDO-treated cells as described (Piacentini et al., 2023), and CC50 (50% Cytotoxic Concentration) was calculated using Prism 8.0 software (Graph-Pad Software Inc.). Microscopical examination of RSV-infected cells was performed using a ZEISS Axio Observer 7 inverted microscope with Apotome III and analyzed using ZEN 3.1 (blue edition) software. Virus production, infection and titration Human RSV-A2 (RSV) was a kind gift from G. Toms, Newcastle University. For RSV production, confluent HEp-2 cell monolayers were infected with RSV at multiplicity of infection (MOI) of 0.1 TCID50 (50% tissue culture infectious dose)/cell; at 72 h post infection (p.i.) the virus was harvested: cells and culture supernatants were centrifuged (5 min, 4000 × g, 4 °C), freeze-thawed 3 times and stored in liquid nitrogen. For virus infection, confluent cell monolayers were infected with different MOI of RSV for 2 h at 37 °C. After the 2 h adsorption period, the viral inoculum was removed and, after repeated washings with PBS, cells were incubated in medium containing 2% FCS. At different times p.i. virus yield was determined by TCID50 infectivity assay, as described (Santoro et al., 1988). INDO IC50 (50% inhibitory concentration) was calculated using Prism 8.0 software. Protein analysis and western blot Whole-cell extracts (WCE) were prepared as described (Coccia et al., 2017) after lysis in High Salt Buffer (40 μl). For Western blot analysis, cell extracts (15 µg/sample) were separated by SDS-PAGE under reducing conditions and blotted to a nitrocellulose membrane. After blocking with 5% skim milk solution, membranes were incubated with the selected antibodies followed by decoration with peroxidase-labeled anti-mouse or anti-rabbit IgG. Primary and secondary antibodies used are listed in Table 1. Protein quantitative evaluation was described previously (Santoro et al., 1989). All results shown are representative of at least three independent experiments.Table 1Antibodies used.Table 1 dummy alt textAntibodySourceCatalogue numberβ-Actin (P)Sigma-AldrichA2066GAPDH (P)CusabioCSB-PA00025A0RbRSV Fusion Protein (2F7) (M)Novus BiologicalsNB110–37246RSV Nucleoprotein (P)Sino Biological40821-T46RSV Phosphoprotein [RSVH102] (M)AbcamAb94965Vinculin (H-10) (M)Santa Cruz Biotechnologysc-25336α-Tubulin (M)Sigma-AldrichT5168EIF2S1 (phospho-S51) (P)Abcamab32157EIF2S1 (M)InvitrogenAHO0802Alexa Fluor™ 555 goat anti-mouseInvitrogenA21422Goat Anti-Mouse IgG (H + L), HRPJackson ImmunoResearch115–035–003Goat Anti-Rabbit IgG (H + L), HRPJackson ImmunoResearch111–035–003(M): Monoclonal; (P): Polyclonal. Table 1Antibodies used.Table 1 dummy alt textAntibodySourceCatalogue numberβ-Actin (P)Sigma-AldrichA2066GAPDH (P)CusabioCSB-PA00025A0RbRSV Fusion Protein (2F7) (M)Novus BiologicalsNB110–37246RSV Nucleoprotein (P)Sino Biological40821-T46RSV Phosphoprotein [RSVH102] (M)AbcamAb94965Vinculin (H-10) (M)Santa Cruz Biotechnologysc-25336α-Tubulin (M)Sigma-AldrichT5168EIF2S1 (phospho-S51) (P)Abcamab32157EIF2S1 (M)InvitrogenAHO0802Alexa Fluor™ 555 goat anti-mouseInvitrogenA21422Goat Anti-Mouse IgG (H + L), HRPJackson ImmunoResearch115–035–003Goat Anti-Rabbit IgG (H + L), HRPJackson ImmunoResearch111–035–003(M): Monoclonal; (P): Polyclonal. Antibodies used. (M): Monoclonal; (P): Polyclonal. RNA extraction and real-time PCR analysis Measurement of RSV F-RNA was performed by quantitative Real-Time PCR (qRT-PCR) analysis, as described (Coccia et al., 2017). Briefly, total intracellular RNA from mock-infected or RSV-infected cells was prepared using ReliaPrep RNA Cell Miniprep System (Promega) and reverse transcription was performed with PrimeScript RT Reagent Kit (Takara), according to the manufacturer’s protocol. qRT-PCR analysis was performed using specific primers listed in Table 2, using SensiFAST SYBR® kit (Bioline) in a CFX96 Real-Time System (Bio-Rad). Relative quantities of selected mRNAs were normalized to ribosomal L34 RNA levels in the same sample (Piacentini et al., 2023). All reactions were made in triplicate using samples derived from at least three biological repeats.Table 2Primers used.Table 2 dummy alt textPrimers used for mRNA gene expressionGenePrimer directionPrimer sequenceF-RSVForward5′- AATGATATGCCTATAACAAATGATCAGAA-3′Reverse5′- TGGACATGATAGAGTAACTTTGCTGTCT-3′L34Forward5′-GGCCCTGCTGACATGTTTCTT-3′Reverse5′-GTCCCGAACCCCTGGTAATAGA-3′ Table 2Primers used.Table 2 dummy alt textPrimers used for mRNA gene expressionGenePrimer directionPrimer sequenceF-RSVForward5′- AATGATATGCCTATAACAAATGATCAGAA-3′Reverse5′- TGGACATGATAGAGTAACTTTGCTGTCT-3′L34Forward5′-GGCCCTGCTGACATGTTTCTT-3′Reverse5′-GTCCCGAACCCCTGGTAATAGA-3′ Primers used. Immunofluorescence microscopy HEp-2 cells were grown in 8-well chamber slides (LabTek II, Nunch), infected with RSV as described above, and treated with INDO or control vehicle after the 2 h adsorption period. After 24 h, cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% TritonX100-PBS (Riccio et al., 2022), and processed for immunofluorescence using selected antibodies (listed in Table 1), followed by decoration with Alexa Fluor 555-conjugated antibodies (Invitrogen). Nuclei were stained with Hoechst 33342 (Invitrogen). Images were captured using a ZEISS Axio Observer-7 inverted microscope with Apotome III and analyzed using ZEN 3.1 (blue edition) software. For confocal microscopy, images were acquired on Olympus FluoView FV-1000 confocal laser scanning system (Olympus America Inc.) and analyzed using Imaris (v6.2) software (Bitplane). Scale-bars are indicated. Images shown in all figures are representative of at least three random fields. Statistical analysis Statistical analyses were performed using Prism 8.0 software (GraphPad Software). Comparisons between two groups were made using Student's t-test; comparisons among groups were performed by one-way ANOVA with Bonferroni adjustments. p values ≤0.05 were considered significant. Data are expressed as the means ± standard deviations (S.D.) of results from duplicate or triplicate samples. Each experiment (in duplicate) was repeated at least twice. Results and discussion To investigate the effect of indomethacin (INDO, Fig. 1C) on RSV replication, HEp-2 cells, an immortalized human respiratory epithelial cell line used to study RSV for decades, were infected with human RSV strain-A2 at an MOI of 0.01 TCID50/cell and treated with different concentrations of INDO or vehicle control after the 2 h adsorption period. At 48 h p.i., virus yield was determined in the supernatant of infected cells by TCID50 infectivity-assay (Fig. 1A, B), whereas the viability of mock-infected HEp-2 cells was determined by MTT-assay (Fig. 1A). INDO was found to have a notable antiviral activity, reducing virus yield dose-dependently with an IC50 of 4 µM, CC50 above 400 μM and selectivity index >100 (Fig. 1A-C). Next, HEp-2 cells infected with RSV at different MOI (0.01, 0.1 or 1 TCID50/cell) were treated with 10 or 100 μM INDO, and virus yield was assessed at 48 h p.i. as described above. As shown in Fig. 1D, INDO-treatment was found to be effective under all conditions used, indicating that INDO antiviral activity is not affected by the number of RSV infectious particles. Moreover, at the concentration of 100 µM, INDO was observed to partially protect HEp-2 cells from RSV-mediated cytopathic effect up to 24 h p.i. (Fig. 1E).Fig. 1Indomethacin inhibits RSV replication in different types of human cells. (A, B) Human HEp-2 cell monolayers infected with RSV at an MOI of 0.01 TCID50/cell were treated with different concentrations of INDO or vehicle (0) after the adsorption period. Virus yield (red line) was determined at 48 h p.i. by TCID50 infectivity assay. Data, expressed as percentage of control (A), represent the mean ± S.D. of triplicate samples. * = p < 0.05; ** = p < 0.01; ANOVA test. Data, expressed as TCID50/ml (B), represent the mean ± S.D. of duplicate samples from a representative experiment of three with similar results. * = p < 0.05; ** = p < 0.01; ANOVA test. In parallel, cell viability (A, blue line) was determined by MTT assay in mock-infected cells. Absorbance (O.D.) of converted dye was measured at λ = 570 nm. Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples. (C) Structure of indomethacin (INDO, upper panel). Indomethacin IC50 and CC50 in μM were calculated using Prism 8.0 software; selectivity index (SI) is indicated (C, lower panel). (D) HEp-2 cell monolayers infected with RSV at an MOI of 0.01, 0.1 or 1 TCID50/cell were treated with INDO (10 or 100 μM) or vehicle (0) after the adsorption period. Virus yield was determined at 48 h p.i. by TCID50 infectivity assay. Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples from a representative experiment of two with similar results. * = p < 0.05; ** = p < 0.01; ANOVA test. (E) Cytoprotective effect of INDO (100 μM) in HEp-2 cells infected with RSV (1 TCID50/cell) at 24 h p.i. (magnification: 100 ×). (F) HEp-2, MRC-5, A549 and 16HBE cells were mock-infected or infected with RSV (0.1 TCID50/cell) and treated with INDO (100 μM) or vehicle (0) after the adsorption period. Virus yield was determined at 48 h p.i. by TCID50 infectivity assay (top panels). Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples. * = p < 0.05; ** = p < 0.01; Student’s t-test. In parallel, cell viability of mock-infected HEp-2, MRC-5, A549 and 16HBE cells treated with 100 μM INDO or vehicle (0) was determined by MTT assay at 48 h after treatment (bottom panels). Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples.Fig 1 dummy alt text Indomethacin inhibits RSV replication in different types of human cells. (A, B) Human HEp-2 cell monolayers infected with RSV at an MOI of 0.01 TCID50/cell were treated with different concentrations of INDO or vehicle (0) after the adsorption period. Virus yield (red line) was determined at 48 h p.i. by TCID50 infectivity assay. Data, expressed as percentage of control (A), represent the mean ± S.D. of triplicate samples. * = p < 0.05; ** = p < 0.01; ANOVA test. Data, expressed as TCID50/ml (B), represent the mean ± S.D. of duplicate samples from a representative experiment of three with similar results. * = p < 0.05; ** = p < 0.01; ANOVA test. In parallel, cell viability (A, blue line) was determined by MTT assay in mock-infected cells. Absorbance (O.D.) of converted dye was measured at λ = 570 nm. Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples. (C) Structure of indomethacin (INDO, upper panel). Indomethacin IC50 and CC50 in μM were calculated using Prism 8.0 software; selectivity index (SI) is indicated (C, lower panel). (D) HEp-2 cell monolayers infected with RSV at an MOI of 0.01, 0.1 or 1 TCID50/cell were treated with INDO (10 or 100 μM) or vehicle (0) after the adsorption period. Virus yield was determined at 48 h p.i. by TCID50 infectivity assay. Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples from a representative experiment of two with similar results. * = p < 0.05; ** = p < 0.01; ANOVA test. (E) Cytoprotective effect of INDO (100 μM) in HEp-2 cells infected with RSV (1 TCID50/cell) at 24 h p.i. (magnification: 100 ×). (F) HEp-2, MRC-5, A549 and 16HBE cells were mock-infected or infected with RSV (0.1 TCID50/cell) and treated with INDO (100 μM) or vehicle (0) after the adsorption period. Virus yield was determined at 48 h p.i. by TCID50 infectivity assay (top panels). Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples. * = p < 0.05; ** = p < 0.01; Student’s t-test. In parallel, cell viability of mock-infected HEp-2, MRC-5, A549 and 16HBE cells treated with 100 μM INDO or vehicle (0) was determined by MTT assay at 48 h after treatment (bottom panels). Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples. To establish whether INDO antiviral activity is dependent on the cell type, the effect of INDO on HEp-2 cells was compared to the drug activity in different types of human respiratory cells including normal lung MRC-5 fibroblasts, alveolar epithelial A549 cells, and human bronchial epithelial 16HBE cells. HEp-2, MRC-5, A549 and 16HBE cells were infected with RSV (0.1 TCID50/cell) and treated with 100 µM INDO after the 2 h adsorption period. At 48 h p.i. virus yield was evaluated in the supernatant of infected cells, whereas the viability of mock-infected cells was assessed as described above. As shown in Fig. 1F, INDO treatment was effective in all types of human respiratory cells tested, inhibiting RSV replication at non-cytotoxic concentrations. Since indomethacin exerts its anti-inflammatory effect by inhibiting cyclooxygenase-1 and cyclooxygenase-2 enzymatic activity (Rouzer & Marnett, 2009), we investigated the effect of the potent COX-1/COX-2 inhibitor aspirin (ASA) on RSV replication. HEp-2 cells were infected with RSV (0.01 TCID50/cell) and treated with different concentrations of INDO or ASA immediately after the adsorption period; at 48 h p.i. virus yield was determined by TCID50 infectivity-assay (Fig. S1A), and the viability of mock-infected cells was determined by MTT-assay (Fig. S1B). As previously shown in the case of different RNA viruses (Amici et al., 2015; Tramontozzi et al., 2024), no antiviral activity was detected in ASA-treated cells up to concentrations as high as 1 mM (Fig. S1), suggesting that the antiviral effect of INDO against RSV is independent of cyclooxygenase activity. Next, to investigate whether INDO may affect RSV receptor-binding or entry into host cells, HEp-2 cells were infected with RSV (0.01 TCID50/cell) and treated with 100 µM INDO 6 h before infection, or only during the 2h-adsorption period (after which time the drug was removed); alternatively, RSV-infected cells were treated immediately after the adsorption period in the absence or presence of 6h-pretreatment. Virus yield was determined at 48 h p.i. as described above. As shown in Fig. 2A, INDO pretreatment did not affect RSV replication when the drug was removed before infection; INDO treatment only during the virus adsorption period was also ineffective; conversely, treatment started after infection remarkably inhibited RSV infectious particles production, even in the absence of drug pretreatment, indicating that INDO acts at post-entry level.Fig. 2Indomethacin treatment decreases RSV F-protein levels acting at the post-entry stage. (A) HEp-2 cells infected with RSV (0.01 TCID50/cell) were treated with 100 μM INDO (+) or vehicle (-) at 6 h before infection (PRE), only during the 2 h adsorption period (ADS) or immediately after the adsorption period in the absence (POST) or the presence of 6 h pretreatment (PRE+POST). Virus yield was determined at 48 h p.i. by TCID50 infectivity assay. Data, expressed as percentage of control, represent the mean ± S.D. of duplicate samples from a representative experiment of two with similar results. * = p < 0.05; ** = p < 0.01; ANOVA test. (B) Schematic representation of RSV Fusion (F) protein structure. Residue numbers 26–524 are indicated. Protein domains are illustrated: DI-III, domains I-III; HRA, -B, and -C, heptad repeats A, B, and C; p27, excised peptide; FP, fusion peptide. The furin cleavage sites (red arrowheads) are shown. (C) Immunoblot analysis of RSV F-protein in HEp-2 cells treated as in (A) at 48 h p.i.; the uncleaved F precursor (F0) and the F1 subunit are indicated (left panels). F0 and F1 levels were determined by densitometric analysis using ImageJ software, normalized to the loading control in the same sample, and expressed as arbitrary units (right panel). Error bars indicate the mean ± S.D. of duplicate samples from a representative experiment of two with similar results. * = p < 0.05; ANOVA test. (D-F) HEp-2 cell monolayers mock-infected (-) or infected (+) with RSV at an MOI of 0.01 TCID50/cell (D,E) or 0.1 TCID50/cell (F) were treated with different concentrations of INDO or vehicle (0) after the adsorption period. At 48 h p.i., levels of the viral fusion protein were determined by immunoblot analysis as in (C). Relative amounts of the F0 precursor and the F1 subunit were determined by densitometric analysis, normalized to β-actin in the same sample, and expressed as arbitrary units (E, left panels; F, lower panel). F1/F0+F1 ratio for each sample is shown (E, right panel). Error bars indicate the mean ± S.D. of duplicate samples from a representative experiment of two with similar results. * = p < 0.05; ** = p < 0.01; *** = p < 0.001; Student’s t-test. (G) Immunofluorescence analysis of RSV-F protein (red) in mock-infected and RSV-infected (1 TCID50/cell) HEp-2 cells treated with INDO (100 μM) or vehicle for 24 h. Nuclei are stained with Hoechst (blue). Merge images are shown. Scale bar, 70 μm. (H) Confocal images of RSV-F protein (red) in HEp-2 cells treated as in (G). Nuclei are stained with Hoechst (blue). Merge images are shown. Scale bar, 20 μm (zoom: 10 μm).Fig 2 dummy alt text Indomethacin treatment decreases RSV F-protein levels acting at the post-entry stage. (A) HEp-2 cells infected with RSV (0.01 TCID50/cell) were treated with 100 μM INDO (+) or vehicle (-) at 6 h before infection (PRE), only during the 2 h adsorption period (ADS) or immediately after the adsorption period in the absence (POST) or the presence of 6 h pretreatment (PRE+POST). Virus yield was determined at 48 h p.i. by TCID50 infectivity assay. Data, expressed as percentage of control, represent the mean ± S.D. of duplicate samples from a representative experiment of two with similar results. * = p < 0.05; ** = p < 0.01; ANOVA test. (B) Schematic representation of RSV Fusion (F) protein structure. Residue numbers 26–524 are indicated. Protein domains are illustrated: DI-III, domains I-III; HRA, -B, and -C, heptad repeats A, B, and C; p27, excised peptide; FP, fusion peptide. The furin cleavage sites (red arrowheads) are shown. (C) Immunoblot analysis of RSV F-protein in HEp-2 cells treated as in (A) at 48 h p.i.; the uncleaved F precursor (F0) and the F1 subunit are indicated (left panels). F0 and F1 levels were determined by densitometric analysis using ImageJ software, normalized to the loading control in the same sample, and expressed as arbitrary units (right panel). Error bars indicate the mean ± S.D. of duplicate samples from a representative experiment of two with similar results. * = p < 0.05; ANOVA test. (D-F) HEp-2 cell monolayers mock-infected (-) or infected (+) with RSV at an MOI of 0.01 TCID50/cell (D,E) or 0.1 TCID50/cell (F) were treated with different concentrations of INDO or vehicle (0) after the adsorption period. At 48 h p.i., levels of the viral fusion protein were determined by immunoblot analysis as in (C). Relative amounts of the F0 precursor and the F1 subunit were determined by densitometric analysis, normalized to β-actin in the same sample, and expressed as arbitrary units (E, left panels; F, lower panel). F1/F0+F1 ratio for each sample is shown (E, right panel). Error bars indicate the mean ± S.D. of duplicate samples from a representative experiment of two with similar results. * = p < 0.05; ** = p < 0.01; *** = p < 0.001; Student’s t-test. (G) Immunofluorescence analysis of RSV-F protein (red) in mock-infected and RSV-infected (1 TCID50/cell) HEp-2 cells treated with INDO (100 μM) or vehicle for 24 h. Nuclei are stained with Hoechst (blue). Merge images are shown. Scale bar, 70 μm. (H) Confocal images of RSV-F protein (red) in HEp-2 cells treated as in (G). Nuclei are stained with Hoechst (blue). Merge images are shown. Scale bar, 20 μm (zoom: 10 μm). Previous studies from our group have shown that INDO causes a dysregulation of viral structural protein expression in a different model of negative-strand RNA virus infection, Vesicular Stomatitis virus (VSV), acting at the translational level, by triggering a rapid activation of the double-stranded RNA-activated protein kinase (PKR), which in turn results in the phosphorylation of eIF2α (eukaryotic initiation factor-2 alpha-subunit), thus inhibiting VSV mRNA translation (Amici et al., 2015). Among the different RSV structural proteins, the Fusion-protein is one of the most studied due to its critical role in mediating fusion and entry into host cells, as well as being responsible, together with the attachment G-glycoprotein, for inducing neutralizing antibodies in-vivo (Langedijk & Bont, 2023). RSV F-protein is a class-I fusion glycoprotein synthesized as a 574-amino-acid inactive precursor called F0 that shares structural similarities with fusion glycoproteins of other members of the Pneumoviridae and Paramyxoviridae (Langedijk & Bont, 2023). In order to become fusion-competent, the F0 precursor needs to be cleaved at two polybasic sites, which are separated by 27 amino-acids (p27), by furin-like host proteases (Fig. 2B). Cleavage, which occurs in the trans-Golgi network during transport to the plasma membrane, generates two subunits, the carboxy-terminal F1-subunit and amino-terminal F2-subunit. F1 is anchored in the viral membrane via a transmembrane region and harbors a N-terminal hydrophobic fusion peptide (FP, Fig. 2B) responsible for cellular membrane insertion; the F2-subunit contributes to F-protein fusogenicity (Langedijk & Bont, 2023). F1 and F2 are covalently linked via two disulfide bonds and associate to form the mature, fusion-competent trimeric F-protein form. As indicated above, the presence of RSV F-protein on the plasma membrane of infected cells triggers cell-to-cell fusion, which results in multinucleate syncytium formation. The effect of INDO on RSV F-glycoprotein expression was therefore investigated. First, HEp-2 cells were treated with 100 µM INDO 6 h before infection with RSV, or were infected with RSV (0.01 TCID50/cell) and treated either only during the 2h-adsorption period or after the adsorption period, as described above; at 48 h p.i. F-protein levels were analyzed in whole-cell extracts (WCE) by immunoblot analysis (IB) using specific antibodies recognizing the F0-precursor and the F1-subunit, followed by scanning densitometry. INDO pretreatment or treatment only during the adsorption period was found not to affect F-protein levels, whereas treatment started after infection caused a remarkable decrease in F-protein expression even in the absence of drug pretreatment (Fig. 2C), confirming that INDO acts at post-entry level. Next, HEp-2 cells were mock-infected or infected with RSV at an MOI of 0.01 (Fig. 2D) or 0.1 (Fig. 2F) TCID50/cell and treated with different concentrations of INDO after the 2 h adsorption period. At 48 h p.i., F-protein levels were analyzed in WCE by immunoblot analysis. At both MOI INDO treatment caused a dose-dependent decrease in F-protein levels (Fig. 2D and F); the F0-precursor and the F1-subunit were found to be similarly affected, indicating that INDO did not significantly alter F0 cleavage (Fig. 2E). Decreased F-protein levels were also detected by immunofluorescence in RSV-infected HEp-2 cells treated with 100 µM INDO for 24 h (Fig. 2G). A decrease in RSV F-mediated syncytia formation was also observed in INDO-treated cells, possibly as a consequence of lower F-protein levels (Fig. 2H). Levels of RSV F-RNA were also determined in INDO-treated cells and compared to the antiviral drug ribavirin (RBV), a purine nucleoside analog known to interfere with RSV RNA synthesis (Aljabr et al., 2016). HEp-2 cells were mock-infected or infected with RSV (0.01 TCID50/cell) and treated with either INDO (10 or 100 µM) or RBV (50 µM) after the 2 h adsorption period. At 48 h p.i. F-RNA levels were assessed by qRT-PCR and virus yield was determined in the supernatant of infected cells, as described above. Ribavirin was found to cause a > 95% decrease in F-RNA expression, whereas INDO treatment only partially reduced F-RNA levels at the concentration of 100 µM, and it did not significantly alter F-RNA levels at 10 µM despite causing a > 60% decrease in viral yield (Fig. S2), suggesting a translational rather than transcriptional effect. To determine whether INDO, as in the case of VSV (Amici et al., 2015), may cause a general block of RSV protein expression, we investigated the effect of the drug on the expression of different viral proteins. As indicated in the Introduction, the RSV single-stranded, nonsegmented negative-sense RNA genome comprises 10 genes encoding 11 structural and non-structural proteins (Fig. 3A). After entry into the host cell, the nucleoprotein (N)-coated genomic RNA is transcribed by the RNA-dependent RNA polymerase complex, consisting of the large subunit (L) and its cofactor phosphoprotein (P), which catalyzes the RNA polymerization during both transcription and replication; the RSV M2–1 processivity cofactor is also required for transcription (Langedijk & Bont, 2023). RSV mRNAs are transcribed starting from the genome 3′-end towards the 5′-end (Fig. 3A) in a sequential polar manner, leading to a gradient in mRNA expression due to the viral polymerase, which utilizes a start-stop mechanism typical of viruses of the Mononegavirales order.Fig. 3Indomethacin treatment does not cause a general block of RSV protein expression in HEp-2 cells. (A) Schematic representation of RSV genome organization. Leader and trailer sequences at genome 3′ and 5′ ends, and genes encoding non-structural proteins (NS1 and NS2), nucleocapsid protein (N), phosphoprotein (P), matrix protein (M), small hydrophobic protein (SH), attachment glycoprotein (G), fusion glycoprotein (F), M2 and large polymerase protein (L) are shown. The M2 gene encodes M2–1 and M2–2 regulatory proteins. RSV mRNAs are transcribed starting from the genome 3′-end towards the 5′-end in a sequential polar manner, leading to a gradient in mRNA expression. (B, C) HEp-2 cell monolayers mock-infected (-) or infected (+) with RSV (0.01 TCID50/cell) were treated with INDO (10–100 μM) or vehicle (0) after the adsorption period. At 48 h p.i., levels of F (F1 subunit), N and P proteins were determined in WCE by immunoblot analysis (B). Levels of F1, P and N proteins were determined by densitometric analysis, normalized to β-actin or α-tubulin in the same sample, and expressed as arbitrary units (C). Error bars indicate the mean ± S.D. of duplicate samples from a representative experiment of two with similar results. * = p < 0.05; ** = p < 0.01; Student’s t-test. (D) HEp-2 cells mock-infected (M) or infected with RSV (1 TCID50/cell) were treated with 100 μM INDO (+) or vehicle (-) after the adsorption period. At different times p.i., levels of RSV F (F1 subunit), P, N and vinculin proteins were analyzed in WCE by IB. (E) In parallel, virus yield was determined in the supernatant of HEp-2 cells treated as in (D) by TCID50 infectivity assay at 24 h p.i.. Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples. * = p < 0.05. Student’s t-test.Fig 3 dummy alt text Indomethacin treatment does not cause a general block of RSV protein expression in HEp-2 cells. (A) Schematic representation of RSV genome organization. Leader and trailer sequences at genome 3′ and 5′ ends, and genes encoding non-structural proteins (NS1 and NS2), nucleocapsid protein (N), phosphoprotein (P), matrix protein (M), small hydrophobic protein (SH), attachment glycoprotein (G), fusion glycoprotein (F), M2 and large polymerase protein (L) are shown. The M2 gene encodes M2–1 and M2–2 regulatory proteins. RSV mRNAs are transcribed starting from the genome 3′-end towards the 5′-end in a sequential polar manner, leading to a gradient in mRNA expression. (B, C) HEp-2 cell monolayers mock-infected (-) or infected (+) with RSV (0.01 TCID50/cell) were treated with INDO (10–100 μM) or vehicle (0) after the adsorption period. At 48 h p.i., levels of F (F1 subunit), N and P proteins were determined in WCE by immunoblot analysis (B). Levels of F1, P and N proteins were determined by densitometric analysis, normalized to β-actin or α-tubulin in the same sample, and expressed as arbitrary units (C). Error bars indicate the mean ± S.D. of duplicate samples from a representative experiment of two with similar results. * = p < 0.05; ** = p < 0.01; Student’s t-test. (D) HEp-2 cells mock-infected (M) or infected with RSV (1 TCID50/cell) were treated with 100 μM INDO (+) or vehicle (-) after the adsorption period. At different times p.i., levels of RSV F (F1 subunit), P, N and vinculin proteins were analyzed in WCE by IB. (E) In parallel, virus yield was determined in the supernatant of HEp-2 cells treated as in (D) by TCID50 infectivity assay at 24 h p.i.. Data, expressed as percentage of control, represent the mean ± S.D. of triplicate samples. * = p < 0.05. Student’s t-test. RSV nucleoprotein (N) and phosphoprotein (P) were selected for these studies. HEp-2 cells were infected with RSV (0.01 TCID50/cell) and treated with 10 or 100 μM INDO after the adsorption period. At 48 h p.i., levels of F, N and P proteins were analyzed in WCE by immunoblot analysis using specific antibodies. As shown in Fig. 3B and C, INDO treatment did not significantly affect N-protein expression and only modestly altered P-protein levels at concentrations that caused a notable decrease in F-protein levels. Next, HEp-2 cells were infected with RSV at high multiplicity of infection (1 TCID50/cell) and treated with 100 μM INDO after the adsorption period. At different times p.i., levels of F, N and P proteins were analyzed as described above, while virus yield was determined at 24 h p.i. in the supernatant of infected cells. Under these conditions, N-protein was detected at early stages of infection, reaching high levels at 24 h p.i. (Fig. 3D). At 24 h p.i., F-protein levels were found to be decreased in INDO-treated cells consistent with the previous results; interestingly, no significant differences in RSV N and P protein levels were detected in INDO-treated cells, as compared to control (Fig. 3D), despite a 90% reduction in viral yield (Fig. 3E). These results indicate that, differently from VSV-infected cells, the antiviral activity of INDO against RSV is not primarily mediated by a general translational block. As indicated above, INDO inhibits VSV protein synthesis by promoting a rapid activation of the PKR kinase, thus triggering eIF2α phosphorylation and leading to VSV mRNA 5′-cap-dependent translation inhibition (Amici et al., 2015). In the case of RSV, treatment with 100 µM INDO was found to cause a moderate increase in eIF2α (Ser51) phosphorylation in HEp-2 cells at early stages of RSV infection, as indicated by the increased ratio of phosphorylated eIF2α (p-eIF2α) to total eIF2α levels (Fig. S3). The differential effects of INDO in RSV versus VSV-infected cells could be due to multiple factors, including the viral life cycle duration. VSV replication cycle is very rapid (2–6 h) and relies on efficient cap-dependent mRNA translation in the early phase of infection (Amici et al., 2015); differently, RSV is characterized by a slower replication kinetics (Wright et al., 2005) and may overcome a temporary translational block. Moreover, it should be noted that RSV infection is known to activate PKR (Groskreutz et al., 2006; Groskreutz et al., 2010); however, only a modest increase in phosphorylated eIF2α levels occurs early in infection. In fact, RSV was found to actively limit eIF2α phosphorylation, both by sequestering PKR via N-protein interaction and favoring eIF2α dephosphorylation by promoting its association to the host phosphatase PP2A, in order to prevent translational shutdown and maintain cellular and viral protein synthesis (Groskreutz et al., 2010; Kerkhofs et al., 2025). This RSV-triggered mechanism to control 5′-cap-dependent translation, may also interfere with the PKR-mediated eIF2α phosphorylation induced by INDO. The mechanism at the basis of the effect on F-protein observed in INDO-treated cells remains to be investigated. It could be hypothesized that the decrease in F-protein as compared to N and P protein levels in INDO-treated cells may be a consequence of RSV transcriptional polarity, being the F gene closer to the genome 5′-end (Fig. 3A) where a modest effect on genes close to the 3′-end of the genome could be amplified. However, it cannot be excluded that INDO may act at multiple levels during the RSV replication cycle, and may interfere with F-protein stability. As described in the Introduction, RSV causes major disease in pediatric patients and can be life-threatening particularly in infants under 6-months; RSV is also recognized to cause a substantial health burden in older adults (Langedijk & Bont, 2023; Li et al., 2022; Nuttens et al., 2024). Severe RSV disease outcome is associated with virus-triggered exacerbated inflammation (Langedijk & Bont, 2023; Lui et al., 2021). Although several F-targeting vaccines and monoclonal antibodies are now available for prevention of RSV disease, there is still an urgent need for anti-RSV drugs efficient in post-infection therapy. Indomethacin, a NSAID used for decades in the clinic for its potent anti-inflammatory and analgesic activity, has been found to also possess antiviral properties against a variety of DNA and RNA viral pathogens in-vitro, as well as in preclinical and clinical studies (Amici et al., 2015; Amici et al., 2006; Ravichandran et al., 2022; Rossen et al., 2004; Tramontozzi et al., 2024; Zhu et al., 2002). We now show that indomethacin at low-micromolar concentrations inhibits RSV replication in in-vitro models, acting at post-entry level and causing a decrease in F-protein expression. The molecular mechanisms underlying the antiviral activity of INDO against RSV remain to be elucidated. However, the fact that INDO is able to inhibit the replication of unrelated DNA and RNA viruses indicates that the drug acts via a host-mediated antiviral mechanism, reducing the risk of viral resistance. This is especially relevant in the case of the RSV fusion protein, as most F-targeting small-molecule candidates pose a substantial risk of inducing drug-resistant mutations (Song et al., 2024; Tang et al., 2021). Moreover, acting at a post-entry level, indomethacin may overcome the known cross-resistance mechanisms of RSV against diverse entry inhibitors (Yan et al., 2014), and may retain therapeutic activity against drug-resistant RSV strains. Whereas the anti-inflammatory effects of indomethacin are mediated by the ability of the drug to block COX-1 and COX-2 enzymatic activity (Rouzer & Marnett, 2009), during VSV and coronavirus infection the antiviral activity was found to be cyclooxygenase-independent and it could not be mimicked by different COX-1/2 inhibitors (Amici et al., 2015; Tramontozzi et al., 2024). Similarly to VSV and coronaviruses, also in the case of RSV infection the potent COX-1/2 inhibitor aspirin did not affect RSV replication up to millimolar concentrations, indicating that INDO anti-RSV activity is cyclooxygenase-independent. Moreover, it should be pointed out that INDO antiviral effects occur at concentrations higher than those needed to inhibit COX activity (10–8–10–9M). In the case of RSV, it is important to note that RSV infection induces COX-2 expression in human lung cells in-vitro, as well as in-vivo in the lungs of both mice and cotton rats, leading to increased prostaglandins production, an effect associated with RSV inflammatory pathogenesis (Richardson et al., 2005; Shirey et al., 2014). Interestingly, indomethacin administration significantly decreased lung pathology, including bronchiolitis, alveolitis, and interstitial pneumonitis, associated with RSV infection in cotton rats, an effect ascribed to the drug anti-inflammatory action rather than antiviral activity (Richardson et al., 2005). Notably, it has been suggested that the balance between COX-2 and 5-lipoxygenase (LO) pathways is critical for development of pathology (COX-2) versus resolution (LO) of RSV-mediated lung injury (Shirey et al., 2014); in this context, treatment with indomethacin was shown to decrease COX-2-mediated lung pathology in RSV-infected LO−/− mice (Shirey et al., 2014). These observations, together with the anti-RSV activity of INDO in human respiratory cells described in the present report, suggest that indomethacin, possessing a direct antiviral activity against RSV in addition to anti-inflammatory properties, may provide a useful tool for the treatment of RSV infections. Funding This research was supported by grants from the Italian Ministry of University and Scientific Research (PRIN project 2010PHT9NF-006) and from the “Fondo Intesa Sanpaolo” (project B/2023/018). Author statement All authors have seen and approved the final version of the manuscript being submitted. The authors declare that the article is the authors' original work, hasn't received prior publication and isn't under consideration for publication elsewhere. A preliminary version of this study was posted on bioRxiv (10.1101/2025.04.28.650844). CRediT authorship contribution statement Caterina Tramontozzi: Writing – review & editing, Writing – original draft, Validation, Investigation, Conceptualization. Anna Riccio: Writing – review & editing, Writing – original draft, Validation, Methodology, Investigation, Conceptualization. Simone La Frazia: Writing – original draft, Project administration, Methodology, Investigation, Conceptualization. Valentina Svicher: Writing – review & editing, Supervision, Project administration, Funding acquisition, Conceptualization. M. Gabriella Santoro: Writing – review & editing, Writing – original draft, Validation, Supervision, Project administration, Funding acquisition, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.